Amylin pramlintide lowers glucose concentration in Type II diabetics on insulin, Phase II data suggest.
Executive Summary
AMYLIN PRAMLINTIDE LOWERS GLUCOSE CONCENTRATION IN DIABETICS TAKING INSULIN, according to results of a one-month Phase II trial of 200 patients with Type II diabetes announced by the company Aug. 7. The Phase II trial evaluated pramlintide 30 mcg q.i.d., 60 mcg q.i.d. and 60 mcg t.i.d. "In all three dose groups, pramlintide administration produced a statistically significant lowering of fructosamine, a surrogate marker which reflects average glucose concentrations over a two-to-three week period," San Diego-based Amylin Pharmaceuticals reported.